{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 56,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a process flow diagram to connect cellular pathology to clinical organ damage.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/9",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Pathophysiology flow from plasma cells to organ damage",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59f3bd9b-18ec-4f1c-806b-3435222b9ec1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: G. Merlini, M. Gertz. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers . 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. PMID: 30361521. F. Lavatelli. Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis. Hemato 2022, 3(1), 47-62; https://doi.org/10.3390/hemato3010005. Quock TP, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139. PMID: 34349108 PMCID: 10.1038/s41408-021-00529-w. R. Lu, T. Richards. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019 Nov-Dec; 10(8): 813-825.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9fca36c-2ce6-4ab0-8259-96b7766afb41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "NXC-201 TARGETS AL AMYLOIDOSIS PLASMA CELLS THAT EXPRESS BCMA ON CELL SURFACE",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e5bc7f3-0602-44c4-9fb9-6329222f1aa3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "AL Amyloidosis: ~30,000 relapsed/refractory U.S. Patients with No FDA approved drugs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "685c1fd9-8b0b-4125-84d7-cfbba9006262",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "66260485-006d-43db-8733-ae450853478d",
      "evidence": "The slide maps the progression from cellular cause to systemic organ damage.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "49cd16bb-edc2-4938-8179-50372f2e2ebe",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slide 9: NXC-201 targets AL amyloidosis plasma cells that express BCMA on cell surface",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 12,
      "from": 7,
      "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
      "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
      "position": 0,
      "objective": "What are the consequences of not adopting NXC-201?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}